Alder, Vitaeris deal

Alder granted newco Vitaeris exclusive, worldwide rights to clazakizumab, an anti-IL-6 mAb. Alder helped co-found Vitaeris to develop clazakizumab, which the newco plans to develop for chronic inflamm...